Les informamos de las siguientes novedades que esperamos que sean de su interés en relación con la Iniciativa de Medicamentos Innovadores (IMI):
Ya está publicado el borrador de los futuros topics de las próximas convocatorias de IMI (www.imi.europa.eu/apply-funding/future-topics), correspondiente al Plan de Trabajo 2018 (www.imi.europa.eu/sites/default/files/uploads/documents/reference-documents/IMI2JU_Amended_AWP_and_Budget_2018.pdf). La fecha prevista de apertura es el 18 de julio y el cierre de la primera fase el 24 de octubre (segunda fase 15 mayo 2019 en caso de evaluación en dos fases).
Por el momento están en consideración los siguientes topics (convocatoria de dos fases):
- Topic: Integrated research platforms enabling patient-centric drug development
- Topic: Blockchain enabled healthcare
- Topic: Microenvironment imposed signatures in tissue and liquid biopsies in immune mediated disease
- Topic: Emerging translational safety technologies and tools for interrogating human immuno-biology
- Topic: Development and validation of translational platforms in support of synaptopathy drug discovery
- Topic: Digital transformation of clinical trials endpoints (part of an IMI programme on digital transformation of clinical trial endpoints)
Asimismo, en esta próxima convocatoria está previsto lanzar el Antimicrobial resistance (AMR) Accelerator Programme, que consiste en tres pilares bajo los cuales se esperan múltiples proyectos:
Pillar A: Capability building network (CBN)
Pillar B: Tuberculosis drug development network (TBDDN)
Pillar C: Company-specific portfolio building networks (PBNs)
Para los Pilares A y B se está considerando incluir un topic de dos fases en cada uno de ellos, mientras que para el pilar C se está considerando una convocatoria de una sola fase con siete topics.
- Pillar A – two-stage topic: Capability building network to accelerate and validate scientific discoveries
- Pillar B – two-stage topic: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
- Pillar C – single-stage Call for proposals with 7 topics
Los topics propuestos para incluir en el pilar C en una convocatoria de una sola fase son los siguientes:
- Topic 1: Progress new assets (One pre new molecular entity (preNME) and one first-time-in-human (FTIH)) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
- Topic 2: Progress novel assets (One first-time-in-human (FTIH)) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline, and cytochrome bc drugs
- Topic 3: Discover and progress novel assets with new mechanisms of action (1 pre-new molecular entity (NME) for tuberculosis (TB) and 1-pre- new molecular entity (NME) for non-tubercular mycobacteria (NTM) and biomarkers for TB and NTM infection
- Topic 4: Determination of gepotidacin levels in tonsils and prostatic tissue
- Topic 5: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
- Topic 6: Functional ethionamide boosters. A novel combination for tuberculosis therapy
- Topic 7: Intravenous treatments of serious infections (urinary tract infections (UTI), intra-addominal infections (IAI) & hospital-acquired pneumonia/ventilator associated pneumonia (HAP/VAP)) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter
Aún es un documento muy preliminar, cambios, incorporaciones y eliminaciones de topics son muy posibles.
Recordarles que estamos a su disposición para posibles consultas y aclarar sus dudas. proyectos1@idival.org e innovacion4@idival.org
